Oncologist Steven O’Day, M.D., internationally known for leading revolutionary immuno-oncology research and advancing the treatment of melanoma, is the new executive director of the John Wayne Cancer Institute and Cancer Clinic and director of Providence Los Angeles Regional Research.
“Dr. O’Day is world-renowned in the field of medical oncology expanding the field of lmmuno-Oncology across tumor types, and with his leadership capabilities he is the ideal person to lead the cancer and research efforts on our campus and in our region,” said Marcel Loh, chief executive of Providence Saint John’s Health Center. “He is a true leader, but first he is a brilliant physician whose groundbreaking research has saved lives.”
Dr. O’Day has been a principal investigator for more than 200 clinical trials including leadership roles in International Phase III trials. He is a professor of medical oncology and director of clinical research and immuno-oncology at the JWCI. He also is is co-director of the Melanoma and Cutaneous Oncology Research Center and has led colleagues in research efforts locally and throughout the seven-state Providence St. Joseph Health system.
“Providence Saint John’s and I share a bold vision for the future,” Dr. O’Day said. “We are creating a state-of-the-art cancer center that combines interdisciplinary clinical excellence around diseases and clinical and translational research around immunotherapy and genomics. We also continue to advance the John Wayne Cancer Institute’s long-standing program of excellence in fellowship training and education.
“We are poised to lead in this revolutionary period of cancer clinical care and research.”
Dr. O’Day has been with the institute since 1994, as the first medical oncologist to join the JWCI’s world-class melanoma clinical and research team. Upon graduating from Williams College in 1983, Dr. O’Day attended Oxford University in England as a visiting scholar where he studied medical ethics. A graduate of the Johns Hopkins School of Medicine, he completed his residency there in internal medicine, followed by a medical oncology fellowship at Harvard’s Dana Farber Cancer Institute in Boston.
“The John Wayne Cancer Institute is recognized across the globe for advancing life-saving research and taking the cutting-edge treatment our teams develop directly to our patients at Saint John’s,” said Erik G. Wexler, chief executive of Providence Saint Joseph Health Southern California, the parent organization. “We are fortunate to have a leader of Dr. O’Day’s quality and experience leading changes in the way we prevent, diagnose and treat cancer across our 51 hospitals."